

FOI REF: 21/453

9<sup>th</sup> September 2021

Tel: 0300 131 4500

Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Q1. How many patients were treated in July 2021 (or latest available month) by the dermatology department with the following drugs:**

• Baricitinib (Olmiant)	0
• Bimekizumab (Bimzelx)	0
• Brodalumab (Kyntheum)	2
• Dupilumab (Dupixent)	19
• Ixekizumab (Taltz)	0
• Risankizumab (Skyrizi)	0
• Guselkumab (Tremfya)	3
• Secukinumab (Cosentyx)	7
• Tildrakizumab (Ilumetri)	0
• Ustekinumab (Stelara)	32

**Q2. How many patients were treated in July 2021 (or latest available month) by the rheumatology department with the following drugs:**

• Baricitinib (Olmiant)	69
• Filgotinib (Jyseleca)	0
• Guselkumab (Tremfya)	0
• Ixekizumab (Taltz)	2
• Secukinumab (Cosentyx)	55
• Tofacitinib (Xeljanz)	14
• Upadacitinib (Rinvoq)	0
• Ustekinumab (Stelara)	1

If I can be of any further assistance, please do not hesitate to contact me.

Cont.../

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)